Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) stock fell -3.97% on Thursday to $2.90 against a previous-day closing price of $3.02. With 1.76 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.8 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.0800 whereas the lowest price it dropped to was $2.8600. The 52-week range on LXRX shows that it touched its highest point at $3.79 and its lowest point at $1.31 during that stretch. It currently has a 1-year price target of $6.33. Beta for the stock currently stands at 1.27.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LXRX was up-trending over the past week, with a rise of 0.35%, but this was up by 20.33% over a month. Three-month performance surged to 30.04% while six-month performance rose 30.63%. The stock gained 79.01% in the past year, while it has gained 51.83% so far this year. A look at the trailing 12-month EPS for LXRX yields -0.63 with Next year EPS estimates of -0.44. For the next quarter, that number is -0.18. This implies an EPS growth rate of -2.10% for this year and 32.30% for next year.
Float and Shares Shorts:
At present, 189.01 million LXRX shares are outstanding with a float of 186.84 million shares on hand for trading. On May 14, 2023, short shares totaled 6.45 million, which was 3.41% higher than short shares on Apr 13, 2023. In addition to Mr. Lonnel Coats as the firm’s CEO & Director, Mr. Jeffrey L. Wade J.D. serves as its Pres & CFO.
Through their ownership of 81.33% of LXRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 66.05% of LXRX, in contrast to 51.27% held by mutual funds. Shares owned by individuals account for 10.14%. As the largest shareholder in LXRX with 47.57% of the stake, Invus Public Equities Advisors LL holds 89,778,234 shares worth 89,778,234. A second-largest stockholder of LXRX, BVF Partners LP, holds 16,149,179 shares, controlling over 8.56% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in LXRX, holding 5,240,247 shares or 2.78% stake. With a 1.44% stake in LXRX, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,717,874 shares are owned by the mutual fund manager. The Fidelity Growth Company Fund, which owns about 0.93% of LXRX stock, is the second-largest Mutual Fund holder. It holds 1,749,708 shares valued at 4.18 million. iShares Russell 2000 ETF holds 0.89% of the stake in LXRX, owning 1,684,531 shares worth 4.03 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, LXRX reported revenue of $35.00k and operating income of -$24.01M. The EBITDA in the recently reported quarter was -$23.88M and diluted EPS was -$0.16.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LXRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With LXRX analysts setting a high price target of $10.00 and a low target of $3.00, the average target price over the next 12 months is $6.33. Based on these targets, LXRX could surge 244.83% to reach the target high and rise by 3.45% to reach the target low. Reaching the average price target will result in a growth of 118.28% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded LXRX stock several times over the past three months with 23 Buys and 9 Sells. In these transactions, 563,608 shares were bought while 178,167 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has risen to 9 over the past year. The total number of shares bought during that period was 21,276,068 while 178,167 shares were sold.